A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

ClinicalTrials.gov ID: NCT04065399

Public ClinicalTrials.gov record NCT04065399. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Study identification

NCT ID: NCT04065399
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Syndax Pharmaceuticals; Industry
Enrollment: 447 participants

Conditions and interventions

Conditions

Interventions

cobicistat Drug
revumenib Drug

Drug

Eligibility (public fields only)

Age range: 30 Days and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 4, 2019
Primary completion: Dec 14, 2027
Completion: Dec 14, 2027
Last update posted: Mar 17, 2026

2019 – 2027

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 20

Facility	City	State	ZIP	Site status
City of Hope Comprehensive Cancer Center	Duarte	California	91010	Active, not recruiting
University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital	Los Angeles	California	90033	Completed
Stanford Cancer Institute	Palo Alto	California	94305	Active, not recruiting
University of Colorado	Aurora	Colorado	80045	Recruiting
Florida Cancer Specialists and Research Institute	Sarasota	Florida	34232	Active, not recruiting
Moffitt Cancer Center	Tampa	Florida	33162	Completed
Emory Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
Children's Healthcare of Atlanta	Atlanta	Georgia	30329	Completed
The University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
University of Iowa Hospital	Iowa City	Iowa	52246	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Active, not recruiting
Washington University in St. Louis School of Medicine	St Louis	Missouri	63110	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Completed
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Active, not recruiting
Montefiore Medical Center	New York	New York	10467	Recruiting
Duke University Medical Center	Durham	North Carolina	27110	Recruiting
University of Cincinnati	Cincinnati	Ohio	45267	Completed
Ohio State University	Columbus	Ohio	43201	Recruiting
Oregon Health & Science University	Portland	Oregon	97239	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Active, not recruiting
Huntsman Cancer Institute at the University of Utah	Salt Lake City	Utah	84112	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04065399, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2026 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04065399 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →